1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (1694)
  2. Journal Article (1416)
  3. Review (80)
  4. Editorial (56)
  5. Book Section (35)
  6. Guidelines (24)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3351)
  2. Solid Tumor Oncology Division (3351)
  3. Thoracic Oncology (3351)
  4. GSK Faculty (1056)
  5. Department of Pathology and Laboratory Medicine (797)
  6. Human Oncology and Pathogenesis Program (625)

More Groups

People
  1. Mark Kris (869)
  2. Alexander Drilon (631)
  3. Gregory Riely (599)
  4. Charles Rudin (488)
  5. Marc Ladanyi (414)
  6. Matthew Hellmann (411)

More People

Years
  1. 2025 (73)
  2. 2024 (270)
  3. 2023 (272)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (692)
  2. Journal of Thoracic Oncology (513)
  3. Annals of Oncology (277)
  4. Clinical Cancer Research (156)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (769)
  2. Elsevier Inc. (734)
  3. American Association for Cancer Research (383)
  4. Oxford University Press (350)
  5. Nature Publishing Group (148)
  6. Elsevier Science, Inc. (78)

More Publishers

Results (3351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC
    Meeting Abstract

    Chaft, J. E.; Costa, D. B.; Muzikansky, A.; Shrager, J. B.; Lanuti, M.; Huang, J.; Ramchandran, K.; Rangachari, D.; Huberman, M.; Piotrowska, Z.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors
    Meeting Abstract

    Cardin, D. B.; Park, H.; Diamond, J. R.; Drilon, A. E.; VerMeulen, W. L.; He, X.; Hirai, H.; Soni, N.; Berlin, J.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade
    Meeting Abstract

    Arbour, K. C.; Tuan, L. A.; Rizvi, H.; Yala, A.; Hellmann, M. D.; Barzilay, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%
    Meeting Abstract

    Jimenez Aguilar, E.; Ricciuti, B.; Gainor, J. F.; Nishino, M.; Adeni, A. E.; Subegdjo, S.; Khosrowjerdi, S.; Peterson, R.; Digumarthy, S.; Liu, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial
    Meeting Abstract

    Oezkan, F.; He, K.; Owen, D. H.; Pietrzak, M.; Rusch, V. W.; Chaft, J. E.; Kitzler, R.; Nicholas, A.; Schulze, K.; Johnson, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Yu, H.; Ahn, M. J.; Kim, S. W.; Cho, B. C.; Sequist, L.; Orlov, S.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Sequist, L. V.; Lee, J. S.; Han, J. Y.; Su, W. C.; Yang, J. C. H.; Yu, H.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer
    Meeting Abstract

    Reckamp, K. L.; Akerley, W.; Edelman, M. J.; Halmos, B.; He, K.; Johnson, M.; Mudad, R.; Neal, J. W.; Owonikoko, T. K.; Patel, J. D.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study
    Meeting Abstract

    Ramalingam, S. S.; Saka, H.; Ahn, M. J.; Yu, H.; Horn, L.; Hida, T.; Cantarini, M.; Verheijen, R.; Wessen, J.; Oxnard, G.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save